Why AlzeCure Pharma stock moves
AlzeCure Pharma edged up, an ordinary move for the stock.
Written after the close on ·
Earnings report
Next report: November 11. On its last 16 report days AlzeCure Pharma usually moved about 2.4%. On a normal day it moves 1.6%.
August 26, 2026: −1.87%May 5, 2026: −1.06%February 26, 2026: −6.19%November 11, 2025: +2.31%
Why today
16,415 news analyzed todayAlzeCure Pharma edged up, an ordinary move for the stock.
It moved against a market that fell clearly that day.
Over the last five trading days the shares eased slightly while the market was roughly flat.
Next, watch the earnings report due Wednesday 11 November 2026.
Today's move of +1.66% was 1.0 times a normal day's 1.6%. OMX Stockholm 30 moved −1.01% on the same day.
AlzeCure Pharma +1.66%OMX Stockholm 30 −1.01%Against the market
What analysts expect, and how often they have been right
Analysts’ estimates for AlzeCure Pharma.
Price targets
Latest price 6.12 SEK
Has the share price followed the business?
Price and earnings moved in the same direction: 0 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed +74% and earnings per share went from -0.38 SEK to -0.41 SEK.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.m SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capm SEK
Price and earnings moved in the same direction: 0 out of 3 years.Market cap (Now): 703 m SEKRevenue 2025: 0.0 m SEK
What the key figures say about AlzeCure Pharma
The figures connect what AlzeCure Pharma earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -0.87 SEK–-0.38 SEK. Peers: Oncopeptides -0.76 SEK, Cantargia 0.68 SEK, Flerie -11.21 SEK.
What the company sold during the year.
2022–2025: 0.0 m SEK–0.0 m SEK. Peers: Oncopeptides 104 m SEK, Cantargia 317 m SEK, Flerie 2.6 m SEK. 2026 estimate: 174 m SEK (174 m SEK–174 m SEK).
Profit as a percentage of shareholders’ money in the company.
2022–2025: −156.3%–−93.0%. Peers: Cantargia 113.5%, Flerie −27.7%.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 4.68–11.02. Peers: Cantargia 1.51, Flerie 0.36.
Cash left after investments, divided by the number of shares.
2022–2025: -1.44 SEK–0.04 SEK. Peers: Oncopeptides -0.42 SEK, Cantargia 0.58 SEK, Flerie -0.35 SEK.
The percentage of assets financed by shareholders’ equity.
2022–2025: 55.8%–85.4%.
What followed similar falls?
Including reinvested dividends, AlzeCure Pharma fell 4.4% over the latest five trading days. Since November 28, 2018, falls at least this large were followed by a higher value 21 trading days later in 25 out of 71 non-overlapping periods. The median was −3.2%, against −2.5% for an ordinary 21-day period, which ended higher 43 times in 100.
Such a fall has not said much about the next month.
−3.2% · 25/71
What to watch next, and why
The earnings report shows how AlzeCure Pharma's revenue and profit have changed.
- Earnings report
The earnings report shows how AlzeCure Pharma's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 16 report days AlzeCure Pharma usually moved about 2.4%. On a normal day it moves 1.6%.
−1.87% −1.06% −6.19% +2.31%
10,000 SEK in AlzeCure Pharma bought on November 28, 2018 is worth 5,790 SEK today, with dividends reinvested.
The same amount in OMX Stockholm 30 with dividends would have become 26,900 SEK.
What would 10,000 SEK in AlzeCure Pharma be worth today? →
What would 10,000 SEK in AlzeCure Pharma be worth today?
5,790 SEK
with dividends reinvested, bought on November 28, 2018. The same amount in OMX Stockholm 30 with dividends would have become 26,900 SEK.
At worst it was worth 874 SEK (February 14, 2025).
The five biggest days of the journey
· +246.6% · the whole market fell 1.2% the same day
· +60.2% · the whole market fell 0.6% the same day
· −35.8% · the whole market fell 1.4% the same day
· −35.5% · the whole market rose 0.9% the same day
· +29.9% · the whole market rose 1.0% the same day
Earlier days
−4.38% market −0.11% AlzeCure Pharma fell slightly over the week while the broader market was roughly flat. Read →
AlzeCure Pharma fell slightly over the week while the broader market was roughly flat.
The main company news came before the week: on 27 October it announced a CEO change, with Johan Sandin taking over temporarily.
The next earnings report is due on Wednesday 11 November 2026.
−0.65% market +0.83% AlzeCure Pharma barely moved, an ordinary day for the stock. Read →
AlzeCure Pharma barely moved, an ordinary day for the stock.
OMX Stockholm 30 rose clearly, so it lagged the market.
The stock fell clearly over the last five trading days, moving against a slightly rising market.
Trading volume was about twice a normal session, so the change drew attention, though the move itself stayed small.
−3.14% market −0.08% AlzeCure Pharma fell clearly. Read →
AlzeCure Pharma fell clearly.
The CEO news came out before the session opened, so it does not explain that move.
No company news from the last session explains the drop.
Over the last five trading days the shares fell slightly, against a slightly rising market.
Trading was about twice its normal level, showing heavy interest.
−1.54% market −0.29% AlzeCure Pharma barely moved, within its usual daily range. Read →
AlzeCure Pharma barely moved, within its usual daily range.
The stock fell slightly as OMX Stockholm 30 also fell slightly.
No company news from the last session explains the move.
Over the last five trading days the shares were roughly flat while the market rose clearly.
Earlier this week the CEO stepped down and the chief scientific officer, Johan Sandin, took over as acting CEO.
−0.62% market +3.01% AlzeCure Pharma was roughly unchanged over the week, moving less than the Stockholm market, which rose clearly. Read →
AlzeCure Pharma was roughly unchanged over the week, moving less than the Stockholm market, which rose clearly.
The company announced a CEO change on 27 October, with research chief Johan Sandin taking over as acting CEO on 28 October while a permanent successor is recruited.
The shares then fell slightly in the last session, in line with a small market decline.
Watch for the next earnings report on Wednesday 11 November 2026.
−0.31% market +0.41% AlzeCure Pharma barely moved, within its usual daily range. Read →
AlzeCure Pharma barely moved, within its usual daily range.
Over the same day OMX Stockholm 30 rose slightly, so AlzeCure moved less than the market.
Over the last five trading days the shares were roughly flat while the market rose sharply.
Trading volume was well below its usual level, so investors were largely inactive.
+3.19% market +0.96% AlzeCure Pharma rose, moving more than the market, which also rose clearly. Read →
AlzeCure Pharma rose, moving more than the market, which also rose clearly.
The company announced after the session closed that CEO Martin Jönsson is leaving, with research chief Johan Sandin stepping in as acting CEO, so that news did not drive the move.
Over the last five trading days the shares fell clearly while the OMX Stockholm 30 was roughly flat, so the decline was company-specific.
Likely reasons for the drop include the company's own sector-wide weakness versus the market, though no news from that window explains it.
−2.13% market +0.41% AlzeCure Pharma fell clearly, moving against the market. Read →
AlzeCure Pharma fell clearly, moving against the market.
No company news explains the move.
The stock also fell clearly over the last five trading days, while OMX Stockholm 30 fell sharply, so it moved more than the market.
Trading volume was about three times normal, a sign of heavy selling interest.
Without company news, the likely drivers are sector sentiment and broader investor selling in healthcare.
−9.30% market −3.67% AlzeCure Pharma fell clearly over the last five trading days, a sharper drop than the broader market. Read →
AlzeCure Pharma fell clearly over the last five trading days, a sharper drop than the broader market.
Over the same days OMX Stockholm 30, the main index of the largest Swedish listed companies, fell sharply, so the decline was partly market-wide.
AlzeCure has had no company news in this period, so no specific event explains the move.
Trading was heavy, well above its usual level, which suggests many investors moved their holdings.
−4.91% market −2.51% AlzeCure Pharma fell sharply last session without company news. Read →
AlzeCure Pharma fell sharply last session without company news.
AlzeCure Pharma fell sharply in the last session, more than the broader market.
OMX Stockholm 30, the main index of large Swedish companies, also fell sharply that day.
Over the last five trading days the stock fell clearly, again more than the market.
Trading volume was roughly double a normal session, so many shares changed hands.
−1.42% market +0.17% AlzeCure Pharma dipped without company news. Read →
AlzeCure Pharma dipped without company news.
The stock fell slightly while the broader Stockholm market was roughly flat.
Over the last five trading days, it also fell slightly and moved more than the market did.
The move was ordinary for this stock, and trading volume was around its usual level.
It likely reflects normal selling in a small biotech share rather than any specific event.
+0.85% market +1.25% AlzeCure Pharma rose slightly, in line with a clearly rising market. Read →
AlzeCure Pharma rose slightly, in line with a clearly rising market.
Its moves over the last five trading days were stronger than the market's, though the news flow was mostly about upcoming investor presentations rather than a fresh catalyst.
The most likely background is the recent licensing deals with Eli Lilly and QuantumCell for two Alzheimer's projects, which investors may still be digesting, while broad Stockholm market strength lifted most stocks.
Next, watch the CEO's update at the Aktiespararna event on 14 October and the Redeye Neurology Day presentation on 15 October.
+5.03% market +1.19% AlzeCure Pharma rose clearly over the last five trading days, moving more than the broader Stockholm market, which edged up slightly over the same stretch. Read →
AlzeCure Pharma rose clearly over the last five trading days, moving more than the broader Stockholm market, which edged up slightly over the same stretch.
The company has been in the spotlight with upcoming investor presentations in Stockholm, where its CEO Martin Jönsson is set to update on its pipeline and on the recent licensing deals with Eli Lilly and QuantumCell.
These deals, which out-license Alzheimer's projects, likely support investor interest in the stock.
Watch for the company's commentary at these events and any further news on how the partnerships progress.
−1.12% market −0.62% AlzeCure Pharma slipped slightly without company news. Read →
AlzeCure Pharma slipped slightly without company news.
Over the last five trading days it rose clearly, outpacing a market that also rose clearly.
The move in the last session matched the market's slight dip, with no company-specific catalyst; the week's gains likely reflect investor interest ahead of the company's upcoming investor presentations on 14 and 15 October, where CEO Martin Jönsson is expected to update on the recent licensing deals with Eli Lilly and QuantumCell.
+5.03% market +0.36% AlzeCure rose sharply as investor-event focus built. Read →
AlzeCure rose sharply as investor-event focus built.
Over the last five trading days AlzeCure Pharma rose slightly, outpacing a roughly flat Stockholm market, with the sharpest gain coming in the latest session.
The likely driver is the run of investor presentations this week — the company is due to update shareholders on its Alzheimer's and pain projects, including the recently signed licensing deals with Eli Lilly and QuantumCell, at two Stockholm events.
Those deals, which license out two Alzheimer's programmes, are the kind of concrete validation that can lift a small biotech, though the timing of the move suggests anticipation of the updates rather than the deals themselves.
Watch whether the presentations add fresh detail on how those partnerships are progressing.
Learn more · Why do stocks move on earnings day? · Why do stocks go up and down?